Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Bekämpa Alzheimers genom sömn och träning (CASE)

23 oktober 2026 uppdaterad av: Azizi Seixas, University of Miami

Bekämpa Alzheimers genom sömn och träning (CASE)

The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

60

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Florida
      • Miami, Florida, Förenta staterna, 33136
        • Rekrytering
        • University of Miami Hospitals
        • Kontakt:
        • Huvudutredare:
          • Azizi A Seixas, PhD
        • Underutredare:
          • Alberto Ramos, MD
        • Kontakt:
        • Underutredare:
          • Debbie Chung, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

55 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Aged 55-80 years at the time of the screening visit
  2. Able to ambulate safely and independently
  3. Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
  4. Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
  5. Able to operate a digital device like mobile phone or computer
  6. Able and willing to provide venous blood samples
  7. Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
  8. Able to self-report a history of cognitive changes or impairment
  9. Be cognitively able (including those with and without MCI) and willing to provide informed consent
  10. Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle

Exclusion Criteria:

  1. Severe mobility limitations that prevent safe participation in moderate exercise protocols
  2. Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
  3. Inability to complete intake screening procedures
  4. Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
  5. Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
  6. Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
  7. Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
  8. Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
  9. Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
  10. Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Sleep Only Group

Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Aktiv komparator: Exercise Only Group

Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off).

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

Aktiv komparator: Exercise and Sleep Group

Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Glycated Hemoglobin (HbA1c) Levels
Tidsram: Up to Week 8

Measured from blood sample

Up to Week 8
Total Cholesterol Levels
Tidsram: Up to Week 8

Measured from blood sample

Up to Week 8
Triglycerides Levels
Tidsram: Up to Week 8

Measured from blood sample

Up to Week 8
High-sensitivity C-reactive protein (hs-CRP) Levels
Tidsram: Up to Week 8

Measured from blood sample

Up to Week 8
Low-Density Lipoprotein (LDL) Levels
Tidsram: Up to Week 8

Measured from blood sample

Up to Week 8
C-Peptides
Tidsram: Up to Week 8

Measured from blood sample

Up to Week 8
High-Density Lipoprotein (HDL) Levels
Tidsram: Up to Week 8

Measured from blood sample

Up to Week 8
Cognitive Function
Tidsram: Up to 8 weeks

Cognitive function gauged from Altoida's Digital Neuro-Signatures

Up to 8 weeks
Insulin Levels
Tidsram: Up to 8 weeks

Measured from blood sample

Up to 8 weeks
Neurofilament light chain
Tidsram: Up to Week 8

Measured from blood sample

Up to Week 8

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Total Sleep Duration
Tidsram: Up to Week 8

Measured from Elemind

Up to Week 8
Slow Wave Sleep Duration
Tidsram: Up to Week 8

Measured from Elemind

Up to Week 8
%Slow-wave Sleep
Tidsram: Up to Week 8

Measured by Elemind headband

Up to Week 8
Rapid Eye Movement Duration
Tidsram: Up to Week 8

Measured by Elemind headband

Up to Week 8
%REM
Tidsram: Up to Week 8

Measured by Elemind headband

Up to Week 8
Light Non-Rapid Eye Movement Duration
Tidsram: Up to Week 8

Measured by Elemind headband

Up to Week 8
%Light Non-Rapid Eye Movement Sleep
Tidsram: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Efficiency
Tidsram: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Onset Latency
Tidsram: Up to Week 8

Measured by Elemind headband

Up to Week 8
Restlessness (Restless Bouts/Hour during Sleep)
Tidsram: Up to Week 8

Measured by Elemind headband

Up to Week 8

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Light Exposure
Tidsram: Up to Week 8

Measured by LYS Device

Up to Week 8
Psychosocial Metrics
Tidsram: Up to Week 8

Measured by Questionnaires

Up to Week 8

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Azizi A Seixas, PhD, University of Miami

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 mars 2023

Primärt slutförande (Beräknad)

30 december 2028

Avslutad studie (Beräknad)

30 december 2028

Studieregistreringsdatum

Först inskickad

19 april 2021

Först inskickad som uppfyllde QC-kriterierna

19 april 2021

Första postat (Faktisk)

22 april 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

27 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera